16-1209337-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -15 ACMG points: 0P and 15B. BP4_StrongBP6_ModerateBP7BS1BS2
The NM_021098.3(CACNA1H):c.3669C>T(p.Ala1223Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00138 in 1,597,962 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.0011 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0014 ( 2 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.747
Publications
2 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -15 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.48).
BP6
Variant 16-1209337-C-T is Benign according to our data. Variant chr16-1209337-C-T is described in ClinVar as Benign. ClinVar VariationId is 460094.Status of the report is criteria_provided_single_submitter, 1 stars.
BP7
Synonymous conserved (PhyloP=0.747 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00109 (166/152324) while in subpopulation NFE AF = 0.00193 (131/68020). AF 95% confidence interval is 0.00166. There are 0 homozygotes in GnomAd4. There are 76 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High AC in GnomAd4 at 166 AD gene.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 34 | 1 | ENSP00000454990.2 | |||
| CACNA1H | ENST00000711493.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 34 | ENSP00000518778.1 | ||||
| CACNA1H | ENST00000565831.7 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 34 | 1 | ENSP00000455840.1 | |||
| CACNA1H | ENST00000711450.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 35 | ENSP00000518762.1 | ||||
| CACNA1H | ENST00000564231.6 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 35 | 1 | ENSP00000457555.2 | |||
| CACNA1H | ENST00000638323.1 | c.3630C>T | p.Ala1210Ala | synonymous_variant | Exon 17 of 35 | 5 | ENSP00000492267.1 | |||
| CACNA1H | ENST00000562079.6 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 34 | 1 | ENSP00000454581.2 | |||
| CACNA1H | ENST00000711438.1 | c.3630C>T | p.Ala1210Ala | synonymous_variant | Exon 17 of 34 | ENSP00000518754.1 | ||||
| CACNA1H | ENST00000711482.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 36 | ENSP00000518771.1 | ||||
| CACNA1H | ENST00000711485.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 35 | ENSP00000518774.1 | ||||
| CACNA1H | ENST00000711455.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 36 | ENSP00000518768.1 | ||||
| CACNA1H | ENST00000711483.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 35 | ENSP00000518772.1 | ||||
| CACNA1H | ENST00000711456.1 | c.3669C>T | p.Ala1223Ala | synonymous_variant | Exon 17 of 34 | ENSP00000518769.1 | ||||
| CACNA1H | ENST00000621827.2 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 37 | 6 | ENSP00000518766.1 | ||||
| CACNA1H | ENST00000637236.3 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*1582C>T | non_coding_transcript_exon_variant | Exon 17 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*3116C>T | non_coding_transcript_exon_variant | Exon 16 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711484.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 35 | ENSP00000518773.1 | |||||
| CACNA1H | ENST00000711486.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 37 | ENSP00000518775.1 | |||||
| CACNA1H | ENST00000711487.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 36 | ENSP00000518776.1 | |||||
| CACNA1H | ENST00000711488.1 | n.3669C>T | non_coding_transcript_exon_variant | Exon 17 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000640028.1 | n.*1582C>T | 3_prime_UTR_variant | Exon 17 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*3116C>T | 3_prime_UTR_variant | Exon 16 of 34 | ENSP00000518758.1 |
Frequencies
GnomAD3 genomes AF: 0.00109 AC: 166AN: 152206Hom.: 0 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
166
AN:
152206
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000955 AC: 219AN: 229278 AF XY: 0.00103 show subpopulations
GnomAD2 exomes
AF:
AC:
219
AN:
229278
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00141 AC: 2035AN: 1445638Hom.: 2 Cov.: 32 AF XY: 0.00140 AC XY: 1006AN XY: 719604 show subpopulations
GnomAD4 exome
AF:
AC:
2035
AN:
1445638
Hom.:
Cov.:
32
AF XY:
AC XY:
1006
AN XY:
719604
show subpopulations
African (AFR)
AF:
AC:
10
AN:
33452
American (AMR)
AF:
AC:
15
AN:
44676
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
26086
East Asian (EAS)
AF:
AC:
0
AN:
39662
South Asian (SAS)
AF:
AC:
23
AN:
86232
European-Finnish (FIN)
AF:
AC:
29
AN:
38104
Middle Eastern (MID)
AF:
AC:
3
AN:
5764
European-Non Finnish (NFE)
AF:
AC:
1898
AN:
1111436
Other (OTH)
AF:
AC:
57
AN:
60226
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.480
Heterozygous variant carriers
0
121
242
363
484
605
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
68
136
204
272
340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00109 AC: 166AN: 152324Hom.: 0 Cov.: 33 AF XY: 0.00102 AC XY: 76AN XY: 74482 show subpopulations
GnomAD4 genome
AF:
AC:
166
AN:
152324
Hom.:
Cov.:
33
AF XY:
AC XY:
76
AN XY:
74482
show subpopulations
African (AFR)
AF:
AC:
12
AN:
41580
American (AMR)
AF:
AC:
7
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3470
East Asian (EAS)
AF:
AC:
0
AN:
5176
South Asian (SAS)
AF:
AC:
3
AN:
4830
European-Finnish (FIN)
AF:
AC:
8
AN:
10624
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
131
AN:
68020
Other (OTH)
AF:
AC:
5
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
12
23
35
46
58
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jan 13, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.